Previous research from the Adli laboratory showed an abundance of PRMT5—an enzyme known for its role in regulating gene expression—in chemotherapy-resistant ovarian cancer. In the current ...

Tango Therapeutics, a biotech company focused on synthetic lethality and PRMT5 inhibition, has two PRMT5 inhibitors in clinical development. Tango's shares spiked after positive data from Mirati ...

"Dosing the first patient in the TNG456 Phase I/II trial marks a significant step for us and for patients with MTAP-deleted GBM," Adam Crystal, Tango's president of R&D, said in a statement. "People ...

Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution ...

Protein arginine methyltransferase 5 (PRMT5) overexpression has been linked to promoting the tumor phenotype in several cancers. Using an innovative AlphaLISA-based high-throughput screening ...

Shares in Tango fell 26% to $3.81 in premarket trading. TNG908 is a MTA-cooperative PRMT5 inhibitor. In cells with MTAP deletion, a mutation found in 10% to 15% of solid tumors, the metabolite MTA ...

Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering. PRMT5, or ...

Previous research has shown that selective inhibition of protein arginine methyltransferase 5 (PRMT5) in the presence of MTA may be considered a potential therapeutic strategy for the treatment of ...

Amgen and Ideaya Biosciences are winding down their cancer combination study, closing off one way the Big Biotech was looking to dial up the efficacy of its PRMT5 inhibitor AMG 193. The ...

In preclinical studies, Apeiron has demonstrated that GTA182 is a potent and selective PRMT5 inhibitor exhibiting greater than 100-fold selectivity for MTAP deleted tumor cell lines. GTA182 is ...